Sandip P. Patel, MD, discusses the role of immunotherapy combinations in lung cancer.
Sandip P. Patel, MD, medical oncologist, associate professor of medicine at the University of California San Diego School of Medicine, discusses the role of immunotherapy combinations in lung cancer.
Patient selection is critical to determine whether a patient is best suited to receive chemoimmunotherapy or chemoimmunotherapy/VEGF inhibitor combinations, says Patel.
Molecular testing plays an important role in terms of treatment selection, Patel adds.
Similar to how histological diagnoses can influence treatment selection, molecular profiling should be obtained prior to therapy initiation for patients with stage IV lung cancer, concludes Patel.